Opdivo nivolumab: Phase Ib data

Data from a cohort of 23 patients with relapsed or refractory classical Hodgkin’s lymphoma in the open-label, U.S. Phase Ib CheckMate -039 trial showed that IV Opdivo led to an ORR of 87%, including 4

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE